October 22, 2018

Heat Biologics to Present at Precision: Lung Cancer World R&D Summit

DURHAM, NC /ACCESSWIRE / October 22, 2018 / HeatBiologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced that Jeff Hutchins, Ph.D. Chief Scientific and Operating Officer, plans to present "The Clinical Effectiveness of an Immuno-oncology Combination Utilizing a Multi-antigen T-cell Activation Platform with Immune Checkpoint Inhibition" at the Precision: Lung Cancer World R&D Summit. The conference is being held on October 29-30, 2018 at the Wyndam Boston Beacon Hill in Boston, Massachusetts.

Event: Precision: Lung Cancer World R&D Summit

Date: Monday, October 29, 2018

Time: 3:00 PM (Eastern Time)

About Precision: Lung Cancer World R&D Summit

Precision: Lung Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations. Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using of CD8+ "Killer" T-cells. Our T-Cell Activation Platform (TCAP) produces therapies designed to turn "cold" tumors "hot" and be administered in combination with checkpoint therapies and other immuno-modulators to increase their effectiveness. HS-110 is our first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Our *ComPACT* technology is the first potential, dual-acting immunotherapy designed to deliver T-cell activation and co-stimulation in a single product. We are currently enrolling patients in our Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. We also have numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.

Media and Investor Relations Contact

David Waldman

+1 919 289 4017

investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.